(Q36271949)

13 August 2017

1 reference

title

State of the art in therapy for non-small cell lung cancer (English)

1 reference

13 August 2017

1 reference

Janessa J Laskin

1

1 reference

13 August 2017

Alan B Sandler

series ordinal

2

1 reference

13 August 2017

publication date

1 January 2005

1 reference

13 August 2017

1 reference

13 August 2017

volume

23

1 reference

13 August 2017

issue

5

1 reference

13 August 2017

page(s)

427-442

1 reference

13 August 2017

cites work

Cancer statistics, 2004

1 reference

Revisions in the International System for Staging Lung Cancer

21 January 2018

1 reference

The role of post-operative radiotherapy in non-small-cell lung cancer: a multicentre randomised trial in patients with pathologically staged T1-2, N1-2, M0 disease. Medical Research Council Lung Cancer Working Party

21 January 2018

1 reference

Randomized Study of Adjuvant Chemotherapy for Completely Resected Stage I, II, or IIIA Non-Small-Cell Lung Cancer

21 January 2018

1 reference

Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer.

21 January 2018

1 reference

A randomized trial of adjuvant chemotherapy with uracil-tegafur for adenocarcinoma of the lung

21 January 2018

1 reference

A randomized trial comparing preoperative chemotherapy plus surgery with surgery alone in patients with non-small-cell lung cancer.

21 January 2018

1 reference

A randomized trial comparing perioperative chemotherapy and surgery with surgery alone in resectable stage IIIA non-small-cell lung cancer.

21 January 2018

1 reference

Preoperative chemotherapy followed by surgery compared with primary surgery in resectable stage I (except T1N0), II, and IIIa non-small-cell lung cancer

21 January 2018

1 reference

Improved survival in stage III non-small-cell lung cancer: seven-year follow-up of cancer and leukemia group B (CALGB) 8433 trial.

21 January 2018

1 reference

A randomized trial of induction chemotherapy plus high-dose radiation versus radiation alone in stage III non-small-cell lung cancer

21 January 2018

1 reference

Induction chemotherapy followed by concomitant chemoradiotherapy for non-small cell lung cancer

21 January 2018

1 reference

Carboplatin plus vinorelbine with concomitant radiation therapy in advanced non-small cell lung cancer: a phase I study

21 January 2018

1 reference

Randomized phase II study of cisplatin with gemcitabine or paclitaxel or vinorelbine as induction chemotherapy followed by concomitant chemoradiotherapy for stage IIIB non-small-cell lung cancer: cancer and leukemia group B study 9431.

21 January 2018

1 reference

Optimizing chemoradiation therapy approaches to unresectable stage III non--small cell lung cancer

21 January 2018

1 reference

Consolidation Docetaxel After Concurrent Chemoradiotherapy in Stage IIIB Non–Small-Cell Lung Cancer: Phase II Southwest Oncology Group Study S9504

21 January 2018

1 reference

Continuous, hyperfractionated, accelerated radiotherapy (CHART) versus conventional radiotherapy in non-small cell lung cancer: mature data from the randomised multicentre trial. CHART Steering committee

21 January 2018

1 reference

Southwest Oncology Group phase II trial of concurrent carboplatin, etoposide, and radiation for poor-risk stage III non-small-cell lung cancer

21 January 2018

1 reference

The economics of lung cancer management in Canada.

21 January 2018

1 reference

Mitomycin, ifosfamide, and cisplatin in unresectable non-small-cell lung cancer: effects on survival and quality of life

21 January 2018

1 reference

Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non--small-cell lung cancer: a Southwest Oncology Group trial

21 January 2018

1 reference

Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer

21 January 2018

1 reference

Phase III randomized trial comparing three platinum-based doublets in advanced non-small-cell lung cancer.

21 January 2018

1 reference

Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: the TAX 326 study group

21 January 2018

1 reference

Cisplatin plus gemcitabine versus a cisplatin-based triplet versus nonplatinum sequential doublets in advanced non-small-cell lung cancer: a Spanish Lung Cancer Group phase III randomized trial

21 January 2018

1 reference

Phase III trial comparing a defined duration of therapy versus continuous therapy followed by second-line therapy in advanced-stage IIIB/IV non-small-cell lung cancer.

21 January 2018

1 reference

Duration of chemotherapy in advanced non-small-cell lung cancer: a randomized trial of three versus six courses of mitomycin, vinblastine, and cisplatin

21 January 2018

1 reference

Symptom relief with MVP (mitomycin C, vinblastine and cisplatin) chemotherapy in advanced non-small-cell lung cancer

21 January 2018

1 reference

Phase III trial of gemcitabine plus cisplatin versus cisplatin alone in patients with locally advanced or metastatic non-small-cell lung cancer

21 January 2018

1 reference

Cisplatin-based therapy for elderly patients with advanced non-small-cell lung cancer: implications of Eastern Cooperative Oncology Group 5592, a randomized trial

21 January 2018

1 reference

Chemotherapy for elderly patients with advanced non-small-cell lung cancer: the Multicenter Italian Lung Cancer in the Elderly Study (MILES) phase III randomized trial

21 January 2018

1 reference

Second-line chemotherapy in relapsing or refractory non-small-cell lung cancer: a review

21 January 2018

1 reference

Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy.

21 January 2018

1 reference

Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group.

21 January 2018

1 reference

Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy

21 January 2018

1 reference

Epidermal growth factor-related peptides and their receptors in human malignancies

21 January 2018

1 reference

The epidermal growth factor receptor-tyrosine kinase: a promising therapeutic target in solid tumors

21 January 2018

1 reference

Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected].

21 January 2018

1 reference

Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial

21 January 2018

1 reference

Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 2.

21 January 2018

1 reference

Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 1.

21 January 2018

1 reference

Gefitinib in Recurrent Non–Small-Cell Lung Cancer: An IDEAL Trial?

21 January 2018

1 reference

Bronchioloalveolar pathologic subtype and smoking history predict sensitivity to gefitinib in advanced non-small-cell lung cancer.

21 January 2018

1 reference

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy

21 January 2018

1 reference

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1081/CNV-67172

1 reference

13 August 2017

1 reference